Read by QxMD icon Read

Chronic hepatits c

Maike Hofmann, Robert Thimme
MAIT cells are an abundant innate-like T-cell subset that is defined by the invariant T-cell receptor (iTCR) V-alpha chain Vα7.2-Jα33. Little is currently known about their frequency and function in chronic hepatitis C virus (HCV) infection and their fate after therapy-mediated HCV elimination by direct acting antivirals (DAA). In this issue of the European Journal of Immunology, Hengst et al. [Eur. J. Immunol. 2016. 46: 2204-2210] give important novel insights into the biological role of MAIT cells in a relevant human chronic viral infection by showing that first, MAIT cells are only present at low frequencies in chronic HCV infection; second, circulating MAIT cells in HCV patients also display an altered phenotype; third, they are impaired in their MR-1-dependent effector functions and finally, and maybe most importantly, MAIT-cell frequency and function was not restored after HCV elimination by DAA therapy...
September 2016: European Journal of Immunology
Tiziana Vescovo, Giulia Refolo, Grazia Vitagliano, Gian Maria Fimia, Mauro Piacentini
Hepatits C virus (HCV) is a major leading cause of hepatocellular carcinoma (HCC). HCV-induced hepatocarcinogenesis is a multi-step process resulting from a combination of pathway alterations that are either caused directly by viral factors or immune-mediated, as a consequence of a chronic inflammation state. Host genetic variation is now emerging as an additional element that contribute to increase the risk of developing HCC. The advent of direct-acting antiviral agents foresees a rapid decline of HCC rate in HCV patients...
July 28, 2016: Clinical Microbiology and Infection
Raíssa Neves Fagundes, Lincoln Eduardo Villela Vieira de Castro Ferreira, Fábio Heleno de Lima Pace
OBJECTIVE: Comparing Health-Related Quality of Life (HRQoL) scores in patients with chronic hepatitis C undergoing double and triple antiviral therapy and analyzing possible factors related to HRQoL. METHOD: HRQoL was assessed using the Short Form 36 and Chronic Liver Disease Questionnaire, which were applied at baseline and at weeks 4, 12 and 16 of treatment to 32 patients divided into two groups: double therapy with pegylated interferon (IFN-PEG) and ribavirin, and triple therapy with PEG-IFN, ribavirin and telaprevir...
December 2015: Revista da Escola de Enfermagem da U S P
Ahmed Abdelsalam, Laila Rashed, Tarek Salman, Lamiaa Hammad, Dina Sabry
BACKGROUND/AIM: Egypt has the highest prevalence rate of Hepatitis C virus (HCV) infection around the globe, where, chronic hepatits C (CHC) is considered a major health problem. The standard treatment of CHC is combination therapy of pegylated interferon and ribavirin. Successful treatment and sustained virological response (SVR) are only achieved in 30% of patients. Major adverse effects and high cost of the treatment makes predicting the treatment output is an important approach. The aim of this study to find an association between Vitamin D concentration and vitamin D receptor (VDR) polymorphisms with achieving SVR...
April 29, 2016: Journal of Digestive Diseases
Cheng-Kung Wu, Kuo-Chin Chang, Po-Lin Tseng, Sheng-Nan Lu, Chien-Hung Chen, Jing-Houng Wang, Chuan-Mo Lee, Ming-Tsung Lin, Yi-Hao Yen, Chao-Hung Hung, Tsung-Hui Hu
BACKGROUND AND AIMS: Patients with chronic hepatitic C (HCV) infection and normal serum alanine transaminase (ALT) levels were considered to have mild disease. In Taiwan, these patients were not suggested for interferon (IFN) based therapies. The aim of study is to compare therapeutic outcomes between HCV patients with normal and elevated ALT levels. METHODS: We conducted a retrospective study on 3241 HCV patients treated by IFN based therapies. Patients with normal ALT levels were classified as group A (n = 186) while those with elevated ALT levels were group B (n = 3055)...
2016: PloS One
E V Beloborodova, I A Goncharova, E I Beloborodova, I L Purlik, T P Kalacheva, O E Akbasheva, M I Rachkovskiy, V A Burkovskaya
AIM OF INVESTIGATION: To estimate the role of polymorphic variants of genes IL4 (C-590T), IL4RA (I50V), TNF (G-308A) and SLC1IAI (D543N) in chronic viral hepatitis progression. MATERIAL AND METHODS: Overall 121 patients with chronic viral hepatitis C and B. RESULTS: Study results have demonstrated, that of all investigated polymorphic variants of genes IL4 (C-590T), IL4RA (150V), TNF (G-308A) and SLC11A1 (D543N) in patients with chronic liver diseases of various etiology the <Val/Val> IL4RA gene variant (II50Val) is associated with HBV-infection chronization...
2015: Experimental & Clinical Gastroenterology
S Fabiani
Interferon (IFN)-inducible protein-10 (IP-10) is a proinflammatory chemokine, binding the chemokine (C-X-C motif) receptor 3 (CXCR3), which is found mainly on activated T cells and natural killer (NK) cells, and plays an important role in T helper (Th) 1 type inflammatory disorders (autoimmune, neoplastic, and infectious diseases). Concerning viral hepatitis, IP-10 appears to be involved on the pathogenesis of liver damage as well as on the extra-hepatic manifestations either protecting or promoting infection, depending on host immune status and genetic background...
2015: La Clinica Terapeutica
Zobair M Younossi, Yushan Jiang, Nathaniel J Smith, Maria Stepanova, Rachel Beckerman
UNLABELLED: Patients with chronic hepatitis C (CHC) exhibit reduced work productivity owing to their disease. Historically, most regimens indicated for CHC genotype 1 (GT1) patients were administered with pegylated interferon (Peg-IFN) and/or ribavirin (RBV), which further compromised work productivity during treatment. The aim of this study was to model the impact of LDV/SOF (ledipasvir/sofosbuvir), the first Peg-IFN- and RBV-free regimen for CHC GT1 patients, on work productivity from an economic perspective, compared to receiving no treatment...
May 2015: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
Romulus Breban, Naglaa Arafa, Sandrine Leroy, Aya Mostafa, Iman Bakr, Laura Tondeur, Mohamed Abdel-Hamid, Wahid Doss, Gamal Esmat, Mostafa K Mohamed, Arnaud Fontanet
BACKGROUND: Most hepatitis C virus (HCV) transmission in Egypt is related to medical injections and procedures. To control the spread of HCV, the Egyptian Ministry of Health initiated awareness and education campaigns, strengthened infection control in health-care facilities, and subsidised anti-HCV treatment. We aimed to investigate the effect of these interventions on the spread of HCV by mathematical modelling. METHODS: We developed a mathematical model of HCV transmission in Zawyat Razin, a typical rural community...
September 2014: Lancet Global Health
Amal A Mohamed, Maggie M Abbassi, Waleed A Hamed, Mohamed A EzzEl-Arab, Ahmed M Aref
BACKGROUND AND AIMS: Zinc has been found to be low in chronic hepatitis patients. Its level was correlated with response to Interferon/ribavirin therapy in patients infected with hepatitis C genotype 1. In Egypt, inexpensive predictors to treatment response in Hepatitis C genotype 4 infected patients are desperately needed. We aim to explore if pretreatment zinc serum levels correlate with response to pegylated- interferon and ribavirin therapy in Egyptian patients. METHODS: This is an observational prospective study where 57 treatment naive hepatitis C genotype 4 infected patients that were Hepatitis B and Human Immunodeficiency virus negative were recruited in a hospital setting...
June 2014: Acta Gastro-enterologica Belgica
Tarık Akar, Aynur Aynıoğlu, Gökhan Dındar, Taner Babür
We've read with great interest the article entitled "Determination of hepatitis C virus genotypes among hepatitis C patients in Eastern Black Sea Region, Turkey" by Buruk et al. published in Mikrobiyol Bul 2013; 47(4): 650-7. In that study, the authors described the determination and distribution of hepatitis C virus (HCV) genotypes in Eastern Black Sea Region comprehensively. According to the current information, the determination of HCV genotypes is the most important factor for the management of therapy and virus-related complications, such as chirrhosis and hepatocellular carcinoma...
July 2014: Mikrobiyoloji Bülteni
Vivek Kesar, Varun Kesar, Viktoriya Khaitova, David Motamed, Thomas Schiano
Telaprevir, a protease inhibitor, was recently approved for management of Chronic Hepatits C (CHC) due to HCV genotype 1. Various RCTs have demonstarted increased incidence of cutaneous adverse effects with use of Telaprevir. Herein, we report two cases of drug rash with eosinophilia and systemic symptoms (DRESS) secondary to Telaprevir use.
February 2014: Journal of Drugs in Dermatology: JDD
Maja Ruzić, Milotka Fabri, Tomislav Preveden, Katarina Kiralj, Sandra Stefan Mikić, Tatjana Vukadinov
BACKGROUND/AIM: Hepatitic C infection (HCV) is a systemic, generalised disease with the prevalence of inflammation in the liver. The aim of this study was to determine the success of treatment for chronic hepatitis C with pegilated interferon alfa 2a and ribavirin in injecting drug users. METHODS: This a 5-year follow-up study included 30 patients [63.3% men and 36.7% women, average age 30.2 years (SD 7.1 years)] injecting drug users in one-year abstinence, with chronic hepatitis C, treated with the pegilated interferon alpha 2a and ribavirin...
August 2013: Vojnosanitetski Pregled. Military-medical and Pharmaceutical Review
Shaikh Samiullah, Devrajai Bikharam, Kalhoro Musarat
OBJECTIVE: To observe any change in value of aspartate aminotransferase to platelet ratio index from the baseline and to compare it with the Hepatitis C virus ribonucleic acid at 12 weeks after the start of interferon-based treatment in patients with Hepatitis C. METHODS: The prospective study, conducted at the Department of Medicine, Liaquat University of Medical and Health Sciences Hospital, Jamshoro, Pakistan, from September 2009 to March 2010, included 158 consecutive, chronic patients of Hepatitis C with grade > or = 2 fibrosis on liver biopsy, or having aspartate aminotransferase/Platelet ratio index of > 1...
October 2012: JPMA. the Journal of the Pakistan Medical Association
V Kh Fazylov, É R Manapova, S V Tkacheva, Iu M Sozinova
Comparative analysis of adverse hematologic effects in 135 patients with with chronic hepatits C on combined antiviral therapy of pegylated and "short lived" forms of alpha-interferon in combination with ribavirin was investigated. As a result of the comparison, the response to antiviral therapy in patients with chronic hepatitis C treated with daily administration of simple interferon-alpha in hematologic data is similar in patients undergoing treatment with pegylated drugs.
2012: Experimental & Clinical Gastroenterology
S D Podymova
Questions of diagnostics, feature of clinic, treatment and preventation of active virus hepatites with parenteral mechanism of transmission of an infection (hepatites B, C, D, G) which make up a significant number of all acute virus hepatites are considered. A wide circulation, features of modern diagnostics and frequency of progress of chronic forms define a problem of diagnostics and treatment of a virus hepatites, as one of important for domestic healthcare. Data about the importance and features serological markers of viruses of a hepatites B, C, D, G, are presented and their clinical interpretation is analyzed...
2012: Experimental & Clinical Gastroenterology
Robert Larbig, Clara Lehman, Dennis Rottländer, Sara Reda, Guido Michels, Uta C Hoppe, Mathias Kochanek
SYMPTOMS: A 40 year old, disoriented, HIV- and Hepatitis B positive male patient was admitted with 40.3 °C. Clinically he presented a sinustachycardia (160/min) and hypotension (70/60 mmHg). INVESTIGATIONS/DIAGNOSIS: Laboratory analyses showed elevated infection parameters, azotemia, proteinuria and thrombopenia. CD(4+)T-helper cells: 320/µl (32 %), HIV RNA: <40 copies/ml, Hepatitis B DNA: 20800 copies/ml. Hantavirus serology (immunofluorescence antibody assay): 1:2048; serotype Puumala...
January 2013: Wiener Medizinische Wochenschrift
Halis Şımşek, Aslı Pinar, Akif Altinbaş, Alparslan Alp, Yasemin H Balaban, Yahya Büyükaşik, Osman Özcebe, Gülşen Hasçelık, Gökhan Gedıkoğlu, Gonca Tatar
BACKGROUND/AIMS: Alpha-1 antitrypsin deficiency causes accumulation of mutant alpha-1 antitrypsin molecules in hepatocytes, and is attributed to severe liver injury even in heterozygous state. However, there is a question as to whether alpha-1 antitrypsin deficiency is only a cause of liver injury or has a worsening effect on the underlying liver disease. We aimed to determine the role of alpha-1 antitrypsin deficiency in the ongoing chronic hepatitic process. MATERIALS AND METHODS: Fifty-four patients with the diagnosis of chronic hepatitis by liver biopsy (36 chronic hepatitis B virus, 8 chronic hepatitis C virus, 7 non-alcoholic steatohepatitis, 2 primary biliary cirrhosis, and 1 autoimmune hepatitis) and 51 age- and sex-matched control subjects chosen from among healthy blood donors were included in the study...
2012: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
Runia Fouad El-Folly, Rania Hamdy El-Kabarity, Naglaa A Arafa
Interleukin-6 (IL-6) is a promising tumor marker for hepatocellular carcinoma; HCC. IL-6 may help to identify a subset of HCC patients with low alpha-fetoprotein (AFP) level, and may serve as complementary tumor marker, however, this has to be clarified. This study assesses the value of measuring serum level of interleukin-6 in patients with chronic liver disease and HCC, and evaluates its sensitivity and specificity in comparison to AFP in early diagnosis of HCC. Seventy five patients with chronic liver disease (CLD) with or without HCC and 25 healthy controls were included...
2010: Egyptian Journal of Immunology
Linda Sher, Linda Jennings, Steven Rudich, Sophoclis P Alexopoulos, George Netto, Lewis Teperman, Milan Kinkhabwala, Robert S Brown, Elizabeth Pomfret, Goran Klintmalm
Chronic hepatitis C virus (HCV) is the most common disease indication for liver transplantation (LT). Outcomes are compromised by near universal recurrence of HCV. A prospective multi-center randomized study to evaluate immunosuppressive strategies in HCV+ transplant recipients provided the opportunity to assess impact of live donor (LD) LT. Two hundred and ninety-five patients undergoing LT for HCV (260 deceased donor [DD] recipients/35 LD recipients), randomized to three regimens, were followed for two yr for patient and graft survival and rate and severity of recurrent HCV...
May 2012: Clinical Transplantation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"